Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: A japanese multicenter study

American Journal of Transplantation

Volumn 14, Issue 1, 2014, Pages 102-114

  Egawa, H ^a   Teramukai, S ^b   Haga, H ^c   Tanabe, M ^d   Mori, A ^c   Ikegami, T ^e   Kawagishi, N ^f   Ohdan, H ^g   Kasahara, M ^h   Umeshita, K ⁱ  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g HIROSHIMA UNIVERSITY   (Japan)

^h NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

ⁱ OSAKA UNIVERSITY   (Japan)

Author keywords

Antibody mediated rejection; blood type incompatible; desensitization; living donor liver transplantation; rituximab

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RITUXIMAB; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ANTIBODY MEDIATED REJECTION; ARTICLE; B LYMPHOCYTE; BLOOD GROUP ABO INCOMPATIBILITY; DESENSITIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTENSIVE CARE UNIT; JAPANESE; KIDNEY DYSFUNCTION; LIVER GRAFT REJECTION; LIVER NECROSIS; LIVER TRANSPLANTATION; LIVING DONOR; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SINGLE DRUG DOSE; SPLENECTOMY; YOUNG ADULT;

ANTIBODY-MEDIATED REJECTION; BLOOD-TYPE INCOMPATIBLE; DESENSITIZATION; LIVING DONOR LIVER TRANSPLANTATION; RITUXIMAB;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BACTERIAL INFECTIONS; BLOOD GROUP INCOMPATIBILITY; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; JAPAN; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MYCOSES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84890984300     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12520     Document Type: Article

References (20)

1. Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M., Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 2008; 47: 143-152.
2. Egawa H, Ohmori K, Haga H, et al. B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation. Liver Transpl 2007; 13: 579-588.
3. Usuda M, Fujimori K, Koyamada N, et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 2005; 79: 12-16.
4. Ikegami T, Taketomi A, Soejima Y, et al. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: A new protocol in ABO incompatible living donor liver transplantation. Transplantation 2009; 88: 303-307.
5. Egawa H, Oike F, Buhler L, et al. Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation 2004; 77: 403-411.
6. Kobayashi T, Saito K., A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee. Xenotransplantation 2006; 13: 136-140.
7. Technical Manual Committee. Antibody titration. In:, Brecher ME, ed. Technical manual. 15th ed. Bethesda, MD: American Association of Blood Banks, 2005.
8. Banff Working Group, Demetris A, Adams D, et al. Update of the International Banff Schema for Liver Allograft Rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology 2000; 31: 792-799.
9. Sawada T, Fuchinoue S, Teraoka S., Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002; 74: 1207-1210.
10. Monteiro I, McLoughlin LM, Fisher A, de la Torre AN, Koneru B., Rituximab with plasmapheresis and splenectomy in abo-incompatible liver transplantation. Transplantation 2003; 76: 1648-1649.
11. Tanabe M, Shimazu M, Wakabayashi G, et al. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 2002; 73: 1959-1961.
12. Kasahara M, Takada Y, Fujimoto Y, et al. Impact of right lobe with middle hepatic vein graft in living-donor liver transplantation. Am J Transplant 2005; 5: 1339-1346.
13. Ogura Y, Hori T, El Moghazy WM, et al. Portal pressure <15 mmHg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. Liver Transpl 2010; 16: 718-728.
14. Alexandre GP, Squifflet JP, De Bruyere M, et al. Splenectomy as a prerequisite for successful human ABO-incompatible renal transplantation. Transplant Proc 1985; 17: 138-143.
15. Tyden G, Kumlien G, Fehrman I., Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immune-adsorption and rituximab. Transplantation 2003; 76: 730-731.
16. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyper immune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315-1322.
17. Raut V, Mori A, Kaido T, et al. Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab. Transplantation 2012; 93: 99-105.
18. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251.
19. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
20. Shirakawa H, Ishida H, Shimazu T, et al. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: A single-center experience. Clin Transplant 2011; 25: 878-884.